<DOC>
	<DOCNO>NCT01035502</DOCNO>
	<brief_summary>The main objective study assess biological activity elacytarabine combination idarubicin patient acute myeloid leukaemia fail first course remission-induction treatment cytarabine ( ara-C ) . In addition , correlation hENT1 ( human equilibrative nucleoside transporter 1 ) overall survival study .</brief_summary>
	<brief_title>A Study Elacytarabine ( CP-4055 ) Plus Idarubicin Second Course Remission-Induction Therapy Patients With Acute Myeloid Leukaemia</brief_title>
	<detailed_description>Elacytarabine ( CP-4055 ) pro-drug ara-C currently use treatment patient acute myeloid leukaemia . Patients nucleoside transporter deficiency ( hENT1 ) seem less benefit cytarabine compare high expression transporter . Preclinical study indicate elacytarabine independent transporter . Therefore , patient low expression hENT1 treat elacytarabine anticipate well outcome compare patient treat ara-C . The main objective study assess biological activity elacytarabine combination idarubicin patient acute myeloid leukaemia . In addition , correlation hENT1 ( human equilibrative nucleoside transporter 1 ) overall survival study . Patients treat elacytarabine plus idarubicin independent hENT1 status . Determination patient ' hENT1 expression level do retrospectively . This study also explore safety profile elacytarabine combination idarubicin .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>1 . Patients confirm diagnosis AML accord WHO classification ( exclude acute promyelocytic leukaemia ) 2 . Patients receive one previous standard dose araCcontaining regimen aim induction complete remission ( CR ) 5 % remain blast cell bone marrow follow first course remissioninduction mean document residual disease ( i.e . circulate blast , persistent chloromas , evident disease day 12 ) . 3 . Patients samples determination hENT1 status leukemic blast cell take prepared diagnosis and/or baseline 4 . Patients must 18 year age old 5 . Patients must ECOG performance status ( PS ) 0 2 6 . Left ventricular ejection fraction ( LVEF ) must &gt; = 45 % measure MUGA scan 2D ECHO within 14 day prior start therapy . 7 . Women childbearing potential ( i.e. , woman premenopausal surgically sterile ) must negative serum urine pregnancy test within 2 week prior begin treatment study 8 . Male female patient must use acceptable contraceptive method duration time study , male also 3 month last elacytarabine dose 9 . Patients must capable understand comply parameter outline protocol , able willing sign write informed consent form 10 . Patients must follow clinical laboratory value : Serum creatinine &lt; = 1.5 x institutional upper limit normal ( ULN ) Total bilirubin &lt; = 1.5 x ULN accord national prescribing information unless consider due Gilbert 's syndrome Alanine aminotransferase ( ALT ) ( SGPT ) , aspartate aminotransferase ( AST ) ( SGOT ) &lt; = 2.5 x ULN unless consider due organ leukemic involvement 11 . Patients must eligible administration idarubicin accord current national prescribing information idarubicin 1 . A history allergic reaction egg , idarubicin and/or anthracyclines component product . A history allergic reaction araC CTCAE grade 3 4 2 . Persistent clinically significant relevant toxicity previous course chemotherapy 3 . A cancer history , accord investigator might confound assessment study endpoints 4 . Patients prior treatment cumulative dose doxorubicin equivalent exceed 300 mg/m2 accord follow calculation index : X/300 + Y/160 &lt; 1 X doxorubicin equivalent dose mg/m2 Y mitoxantrone dose mg/m2 . These calculation use guidance maximum cumulative dose define summary product characteristic ( SPC ) idarubicin . The patient tolerate minimum one course combination therapy 5 . Active heart disease include myocardial infarction within previous 3 month , symptomatic coronary disease , arrhythmias control medication , uncontrolled congestive heart failure . Any NYHA grade 3 4 6 . Known positive status human immunodeficiency virus ( HIV ) 7 . Pregnant nursing patient exclude effect elacytarabine fetus nursing child unknown 8 . Uncontrolled intercurrent illness include , limited uncontrolled infection , psychiatric illness/social situation may reduce compliance study requirement 9 . Patients receive hydroxyurea within last 12 hour prior treatment protocol investigational standard cytotoxic treatment within last 14 day , except first remissioninduction course 10 . Any medical condition , opinion investigator place patient unacceptably high risk toxicity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Cancer</keyword>
	<keyword>CP-4055</keyword>
	<keyword>elacytarabine</keyword>
	<keyword>combination</keyword>
	<keyword>idarubicin</keyword>
	<keyword>Acute myeloid leukaemia ( AML )</keyword>
</DOC>